Vaccines can address coronavirus variants, WHO says

World Health Organisation emergencies chief Mike Ryan says coronavirus vaccines will likely be adapted if they lose their effectiveness against mutations.

A laboratory technologist processes COVID-19 samples at the Bidh Lab in Nepal where oversea coronavirus variants have been recorded.

A laboratory technologist processes COVID-19 samples at the Bidh Lab in Nepal where oversea coronavirus variants have been recorded. Source: AAP

It should be possible to adapt coronavirus vaccines quickly if they lose their effectiveness against mutations, World Health Organisation emergencies chief Mike Ryan says.

"Have a look at influenza. We change the vaccine composition twice a year - for the northern and southern hemisphere - and we're able to issue vaccines very, very quickly to combat the predominant flu strains," Ryan said during a social media question and answer session.

"There's no reason, even down the line, if this virus evolves to a point where our vaccines begin to lose effectiveness, (why we should not be able to vaccinate against COVID-19). We can adapt those vaccines, and I believe we can adapt those vaccines quickly."

The University of Oxford expects efficacy data from a study of its COVID-19 vaccine against the UK variant of the coronavirus by next week, a lead scientist said on Wednesday at a virtual meeting of a US CDC advisory panel.

"Since the middle of December, that (UK) variant has been dominant and spread so rapidly. And so, we should be able to put together an analysis on efficacy against that probably by next week," said Andrew Pollard, director of the Oxford Vaccine Group.

Oxford University has developed the vaccine for the variant along with UK drug maker AstraZeneca.
They will also work on a vaccine version that will target the South African variant of the virus, according to a media report on Tuesday.

British scientists have said the UK variant that is behind a surge in COVID-19 infections in the country may be not only more transmissible but also more lethal - with a mortality risk about 30 per cent higher than other variants.

The Oxford-AstraZeneca duo, once frontrunners, have been left behind in the vaccine race by Pfizer Inc and Moderna Inc, which have both found their vaccines to be effective against the UK variant.

The UK Office for National Statistics (ONS) said on Wednesday people infected with the new UK variant are less likely to report a loss of taste and smell.

The ONS said they were more likely to report "classic" symptoms of the virus such as a cough and a fever.

People in Australia must stay at least 1.5 metres away from others. Check your jurisdiction's restrictions on gathering limits. If you are experiencing cold or flu symptoms, stay home and arrange a test by calling your doctor or contact the Coronavirus Health Information Hotline on 1800 020 080. News and information is available in 63 languages at sbs.com.au/coronavirus.

Please check the relevant guidelines for your state or territory: NSWVictoriaQueenslandWestern AustraliaSouth AustraliaNorthern TerritoryACTTasmania.


Share
3 min read

Published

Updated

Source: AAP


Share this with family and friends


Get SBS News daily and direct to your Inbox

Sign up now for the latest news from Australia and around the world direct to your inbox.

By subscribing, you agree to SBS’s terms of service and privacy policy including receiving email updates from SBS.

Download our apps
SBS News
SBS Audio
SBS On Demand

Listen to our podcasts
An overview of the day's top stories from SBS News
Interviews and feature reports from SBS News
Your daily ten minute finance and business news wrap with SBS Finance Editor Ricardo Gonçalves.
A daily five minute news wrap for English learners and people with disability
Get the latest with our News podcasts on your favourite podcast apps.

Watch on SBS
SBS World News

SBS World News

Take a global view with Australia's most comprehensive world news service
Watch the latest news videos from Australia and across the world